Target intelligence / Profile preview

Patched-1 receptor (PTCH1)

Target
PTCH1
Molecular classification
Receptor, Transmembrane protein, Tumor suppressor, Receptor for Sonic Hedgehog (Hedgehog pathway receptor)
01

Overview

Patched-1 receptor (PTCH1) is a 12-pass transmembrane receptor that acts as the primary receptor for Sonic Hedgehog (SHH) and other Hedgehog ligands. PTCH1 functions as a tumor suppressor by inhibiting the GPCR-like signaling protein Smoothened (SMO) in the absence of Hedgehog ligands. Upon binding of Hedgehog ligands to PTCH1, this inhibition is relieved, allowing propagation of Hedgehog signaling, which influences critical processes during embryogenesis, cell proliferation, tissue patterning, and tumorigenesis. Mutations in PTCH1 can cause constitutive activation of the Hedgehog pathway, contributing to developmental disorders and various cancers such as basal cell carcinoma and medulloblastoma. PTCH1 is a key therapeutic target in Hedgehog pathway-driven tumors, with clinical focus on indirectly targeting its pathway through SMO inhibitors.

Other names
Patched homolog 1PTCHPTCPTC1BCNSNBCCSpatched (Drosophila homolog)HPE7FLJ26746FLJ42602PTC1_HUMAN
02

Mechanism of action

Inhibitors relieve PTCH1-mediated suppression of Smoothened, thus activating Hedgehog pathway signaling. Some drugs (like vismodegib/sonidegib) act on Smoothened to modulate effects downstream of PTCH1 loss or mutation.

03

Biological functions

Signal transductionCell proliferationEmbryonic patterning and developmentTumor suppressionNegative regulator of Smoothened receptor (SMO) in Hedgehog signaling pathway
04

Disease associations

Cancer (including basal cell carcinoma, medulloblastoma, digestive tract tumors, small cell lung cancer)Developmental disorders (holoprosencephaly, cleft lip/palate, Gorlin syndrome)Other: Trichoepithelioma, transitional cell carcinoma of the bladder
05

Safety considerations

On-target adverse effects: Hedgehog pathway modulation can affect normal tissue homeostasis and repairIncreased risk of secondary malignancies and developmental abnormalities in cases of pathway over-activation or inhibition
06

Interacting drugs

Vismodegib

2 more in the full profile.

07

Biomarkers

PTCH1 mutation status (for selection in basal cell carcinoma, medulloblastoma, Gorlin syndrome)GLI1 expression (downstream Hedgehog pathway target gene)

Beyond the preview

Go deeper on Patched-1 receptor (PTCH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Patched-1 receptor (PTCH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call